Corresponding Author: Hiroshi BANDO, MD, PhD, FACP ORCID iD Address: Tokushima University/Medical Research, Nakashowa 1-61, Tokushima 770-0943, Japan. Received date: 19 February 2021; Accepted date: 29 March 2021; Published date: 06 April 2021
Citation: Bando H, Kato Y, Kato Y, Matsuzaki S, Waka S, Ogura K. Changed Diabetic Treatment from Multiple Daily Injection (MDI), Dulaglutide to Xultophy. Asp Biomed Clin Case Rep. 2021 Apr 06;4(1):77-83.
Keywords: Xultophy, Degludec and Liraglutide, Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist, Dual Action of Liraglutide and Insulin Degludec, European Xultophy Treatment Retrospective Audit
Abbreviations: IDegLira: Degludec and Liraglutide; GLP-1RA: Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist; DUAL: Dual Action of Liraglutide and Insulin Degludec; EXTRA: European Xultophy Treatment Retrospective Audit
The patient is a 56-year old (yo) female with type 2 diabetes mellitus (T2DM). Medical histories include persisting T2DM from 35yo, renal stone at 43yo, hypertension from 45yo, photocoagulation for retinopathy on 54yo. An incidentaloma was found in the left adrenal gland, where endocrinological exams were negative for functional tumor. Her diabetic control situation became worse with HbA1c > 10%, then the treatment has been changed from multiple daily injection (MDI), Dulaglutide to Xultophy which is combined agents of degludec and liraglutide (IDegLira). It was provided 10-18 doses daily, and then glucose variability profile was improved satisfactory, suggesting the dual synergistic effects.